Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide.

AUTOR(ES)

Wei, C M

RESUMO

This study reports the cardiovascular and renal actions of a novel and newly synthesized 27-amino acid peptide termed vasonatrin peptide (VNP). VNP is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). This synthetic peptide possesses the 22-amino acid structure of CNP, which is a cardiovascular selective peptide of endothelial origin and is structurally related to ANP. VNP also possesses the five-amino acid COOH terminus of ANP. The current study demonstrates both in vitro and in vivo that VNP possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP.

Documentos Relacionados

• Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.
• Isolated atrial amyloid contains atrial natriuretic peptide: a report of six cases.
• Prostaglandins regulate the synthesis and secretion of the atrial natriuretic peptide.
• Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide.
• Infrared spectroscopic evidence of conformational transitions of an atrial natriuretic peptide.